Dr. Malaisamy Muniyandi
Health Economics Demography Infectious Diseases Tuberculosis Health Technology Assessment Humans Mycobacterium tuberculosis Tuberculosis, Multidrug-Resistant Rifampin Antitubercular Agents Early Diagnosis Molecular Diagnostic Techniques Cost-Benefit Analysis India Health Systems, Economic Evaluations, Quality of Life Infectious Diseases and Tuberculosis Tuberculosis Research and Epidemiology Mycobacterium research and diagnosis Global Health and Epidemiology Healthcare Policy and Management Multi-drug-resistant tuberculosis Drug resistant tuberculosis Multi drug resistant Molecular diagnostics Quality-adjusted life year Disability-adjusted life year Cost-effectiveness analysis Incremental cost-effectiveness ratio Extensively drug-resistant tuberculosis Rapid diagnostic test Tuberculosis diagnosis Data-Driven Disease Surveillance Social epidemiology Economic and Financial Impacts of Cancer Mycobacterium tuberculosis complex Complementary and alternative medicine Economics and Econometrics Epidemiology Health Information Management Surgery

Bio

Dr. Malaisamy Muniyandi is a distinguished scientist in health economics at the National Institute for Research in Tribal Health (ICMR), Jabalpur, India. With a PhD in Health Economics, he has made significant contributions to understanding the economic burden of tuberculosis, particularly catastrophic health expenditures. He has authored over 136 publications, accumulating over 2,500 citations, with an h-index of 25 and i10-index of 55. His work spans health economics, tuberculosis control, and tribal health, reflecting a commitment to evidence-based policy.

Educational Journey

National Institute for Research in Tuberculosis

M.A., MPS., MPhil., PGDMSM., PhD.Head of the Department & Scientist-C Department of Health Economics • Health Economics

Experience

National Institute for Research in Tribal Health

0 - 0

Affiliations

National Institute for Research in Tuberculosis Indian Council of Medical Research

Fellow

Member since 2019

Research

Household Catastrophic Health Expenditure due to Tuberculosis

Article December 29, 2015

Tuberculosis (TB) is disproportionately affects the most economically disadvantaged strata of society. Many studies have assessed the association between poverty and TB, but only a few have assessed the direct financial burden TB treatment and care can place on households. Patient costs can be catastrophic health expenditure for TB affected households in Particularly Vulnerable Tribal Groups (PVTGs). A survey of pulmonary tuberculosis (PTB) was carried out in Saharia dominated Pohri Block of Shivpuri district of Madhya Pradesh state in central India during the period 2013 to 2014. Of 9964 surveyed, 280 PTB cases identified formed the study population for the present study. Among 280 TB patients identified, 220 (79%) cases interviewed at their residence by trained field investigators after obtaining written informed consent. This study demonstrates the economic burden in terms of direct, indirect and total costs for both diagnosis and treatment. In our sample, majority getting treatment free of costs and those who incurred costs, they faced catastrophic TB care expenditure amounted to 10%, which is the proportion of various costs in relation to annual family income. TB is a major cause of impoverishment, as it puts a heavy burden on the family budget, which can force families to absolute poverty.